First approved in 2020, first-in-class microtubule inhibitor Klisyri (tirbanibulin 1%) reached the market in early 2021, joining a short list of therapies in the US that are available for AK ...

The Company also presents preclinical combination data of azenosertib with microtubule inhibitor-based antibody drug ...

CatalYm today announced the presentation of the first preclinical data demonstrating that the company’s clinical-stage ...

These results implicate HDAC6, and possibly SIRT2, modalities as therapeutic targets for diseases exhibiting impaired microtubule transport. The effects of HDAC6 and SIRT2 inhibitors on ...

Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American ...

The company’s lead compound ricolinostat is an oral, selective inhibitor of the microtubule-modifying enzyme histone deacetylase 6 (HDAC6). With first-in-class potential, ricolinostat is ...

ADRX-0134 is a preclinical NaPi2b ADC incorporating AP052, the same clinically validated microtubule inhibitor payload used in Adcentrx's lead program, ADRX-0706 (Nectin-4 ADC), currently ...

Eribulin is a microtubule-dynamics inhibitor, structurally modified analogue of halichondrin B, originally isolated from the marine sponge Halichondria okadai. Its mode of action is distinct from ...

Preclinical in vitro and in vivo data show enhanced anti-tumor activity when combining visugromab, a GDF-15-neutralizing antibody candidate, with approved antibody-drug-conjugate (ADC) treatment ...